The recent partnership between Diversigen and Baylor Miraca Genetics highlights the importance of both human genetics and the microbiome in drug development and ultimately in clinical decision making.
We are in the early days of understanding the scope of the impact of the microbiome but we already know of powerful associations in diseases as diverse as inflammatory bowel disease, diabetes and cancer.
We are excited about this partnership as it leverages real technical and interpretive expertise across across a broad array of genomes relevant to human health.
Read more about their partnership.
Tags: biotech, diagnostics, genetics, healthcare technology, microbiome
Posted in biomedical research, Diagnostics | No Comments »
During his final State of the Union address, President Obama announced he is charging Vice President Biden with leading a new “moonshot” program to accelerate the pace of improvements in cancer care. While the goal is certainly laudable, I share the “sense of déjà vu” that was eloquently expressed by Vinay Prasad in his recent editorial1 in which he recounts the limited progress seen in the Nixon-era War on Cancer, and even more recently in the G.W. Bush era, when then-NCI Director Andrew Van Eschenbach testified that we could rid the world of cancer by 2010 for just $600 million per year.
Read the rest of this entry »
Posted in biomedical research, Diagnostics, Digital health, Our Views | No Comments »